Clinical trials: Vaccine Prophylaxis
Pneumococcal Infections
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
This study will assess the safety, tolerability and immune response of 13-valent pneumococcal conjugate vaccine (13vPnC) compared with 23-valent Pneumococcal Polysaccharide Vaccine (23vPS).
- Trial name
- NCT00427895
- Testing
- 13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
- Where
- 26 sites in United States
- Volunteers
- 2,141 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccine Effectiveness, HPV Vaccination
A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia
The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls/women aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months…
- Conditions
- Vaccine Effectiveness, HPV Vaccination, Single Dose, Immunogenicity
- Trial name
- CervALONE (NCT07256912)
- Testing
- quadrivalent HPV vaccine
- Where
- Zambia
- Volunteers
- 1,266 people, healthy volunteers welcome
- Sponsor
- International Agency for Research on Cancer
Influenza
Zanamivir Versus Trivalent Split Virus Influenza Vaccine
This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and…
- Trial name
- Stop-Flu-2 (NCT00784784)
- Testing
- Fluviral, Zanamivir
- Where
- Canada
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Mount Sinai Hospital, Canada
Human Immunodeficiency Virus, HIV Infections
Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults
This protocol will evaluate the safety and tolerability of the vaccine EnvDNA in healthy adults. DNA-based vaccines are being studied for the prevention of human immunodeficiency virus (HIV), malaria and hepatitis.
- Trial name
- NCT00187148
- Testing
- EnvDNA
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Mumps, Rubella
Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life.
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT00126997
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 54 sites in Finland, Germany and 2 more
- Volunteers
- 1,439 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
The goal of this clinical trial is to learn whether the bacterial vaccine MV130 helps reduce the number of exacerbations in adults with moderate to severe COPD. It will also assess the safety and immune effects of MV130.
- Trial name
- MV130 (NCT01842360)
- Testing
- MV130
- Where
- 7 sites in Spain
- Volunteers
- 198 people
- Sponsor
- Inmunotek S.L.
Vaccine, Crimean-Congo Hemorrhagic Fever
Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever
The goal of this clinical trial is to assess the safety, tolerability and immunogenicity of three dosage levels, and a single or two-dose administration regimen, of the investigational HDT-321 product administered…
- Trial name
- NCT06799013
- Testing
- 10 ug HDT 321, 25ug HDT-321, 50ug HDT-321
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- HDT Bio
Preclinical Alzheimer's Disease, Alzheimer Disease
AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease
This Phase 2 study will evaluate the safety, tolerability, immunogenicity, and amyloid-lowering effect of AV-1959R in cognitively unimpaired adults with preclinical Alzheimer's disease.
- Trial name
- AREVIA (NCT07827768)
- Testing
- AV-1959R
- Volunteers
- 160 people
- Sponsor
- Institute for Molecular Medicine
Prophylaxis Pneumococcal Vaccine
Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)
Evaluate the immunological memory induced by 4 doses of GSK Biologicals' 11valent pneumococcal vaccine; study antibody persistence 30 months after the 4 dose vaccination with GSK Biologicals' 11-valent pneumococcal vaccine in…
- Trial name
- NCT00169507
- Testing
- Pneumococcal (vaccine)
- Where
- 4 sites in Slovakia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.
The immune response of uraemic patients to hepatitis B vaccination is impaired compared to healthy subjects. After vaccination, anti-HBs peak antibody concentrations are reduced.
- Trial name
- NCT00291980
- Testing
- HB-AS02V vaccine, HBVAXPRO vaccine
- Where
- 28 sites in Belgium, Czechia and 1 more
- Volunteers
- 185 people
- Sponsor
- Henogen
Influenza A Virus Infection
Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza
In recent years, influenza viruses that have traditionally infected animals have infected humans as well. The H2N3 influenza virus, which first appeared in pigs in the Midwest United States in 2006, may pose a potential health…
- Trial name
- NCT01175122
- Testing
- H2N3 MO 2003/AA ca Vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19 Prevention
An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" Vaccine
Phase I-II open prospective, two-stage, non-randomized study in healthy volunteers.
- Trial name
- NCT04713488
- Testing
- Sputnik Light
- Where
- Russia
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
COVID-19 Prevention
Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light
The study Global sponsor is planning several parallel studies of Sputnik-Light vector vaccine across the globe in United Arab Emirates, Russia and possibly in other countries in case of confirmation associated with the same…
- Trial name
- SPUTNIK-LIGHT (NCT04741061)
- Testing
- Sputnik Light
- Where
- 15 sites in Russia
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Hantavirus Pulmonary Infection, Immunisation
Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device
This is a Phase 1, randomized, placebo controlled, double-blind, dose escalation trial of 48 males and non-pregnant females, 18-49 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03682107
- Testing
- Andes virus DNA vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Prevention
The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine
Live Attenuated freeze-dried Influenza Vaccine has been licensed for use in 2020 (Approval No.S20200002), the sponsor of this research submitted an new application for non freeze-dried Live Attenuated Influenza Vaccine in 2021.
- Trial name
- NCT05284851
- Testing
- Live Attenuated Influenza Vaccine(non freeze-dried), Live Attenuated Influenza Vaccine(freeze-dried)
- Where
- China
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Covid19, Vaccine Preventable Disease
Study of Gam-COVID-Vac in Adolescents
Double-blind, placebo-controlled study with open dose selection period for safety assessment, tolerance and immunogenicity of the drug "GamKOVID-Vac M, a combined vector vaccine for prevention of coronavirus infection caused by…
- Trial name
- OLSTAD (NCT04954092)
- Testing
- Gam-COVID-vac M
- Where
- 2 sites in Russia
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Hepatitis B
Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders
Hepatitis B is a vaccine preventable infection which can be transmitted through occupational exposure. Approximately 15% of patients will not respond to an initial series of vaccination.
- Trial name
- NCT01126853
- Testing
- Twinrix
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mount Sinai Hospital, Canada
Malaria
Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children
This study will investigate the safety and immunogenicity of 2 candidate malaria vaccines administered according to 3 different vaccination schedules in 5 to 17 months old Ghanaian children.
- Trial name
- NCT00360230
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049, Rabipur
- Where
- 2 sites in Ghana
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Lassa Virus Infection
A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)
This is a randomized, placebo-controlled, single-center, dose finding phase I trial in healthy adult volunteer participants consisting of two phases, an unblinded dose escalation and an observer-blinded treatment phase.
- Trial name
- NCT04055454
- Testing
- MV-LASV
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Prevention of COVID-19 Variant (Omicron JN.1)
Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years
This Phase 1, multi-center, randomized, double-blind, placebo-controlled, dose-escalation study evaluates the safety, tolerability, and immunogenicity of BMI2012, a self-amplifying RNA vaccine candidate targeting the SARS-CoV-2…
- Trial name
- NCT07791186
- Testing
- BMI2012 low-dose, BMI2012 mid-dose, BMI2012 high-dose
- Where
- 3 sites in South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- BMI Korea